Drug Profile
Darapladib
Alternative Names: 480848; SB-480848Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Human Genome Sciences
- Developer GlaxoSmithKline
- Class Acetamides; Fluorobenzenes; Pyrimidinones; Small molecules; Sulfides
- Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Atherosclerosis; Diabetic macular oedema
Most Recent Events
- 12 Nov 2016 Adverse events data from the phase III SOLID-TIMI 52 trial in Atherosclerosis presented at the 89th Annual Scientific Sessions of the American Heart Association
- 01 Aug 2014 GlaxoSmithKline completes a phase I pharmacodynamic trial in Atherosclerosis (in patients with Type-2 diabetes mellitus) in United Kingdom (NCT02058641)
- 30 Jun 2014 Discontinued - Phase-III for Atherosclerosis in South Korea, Japan, Norway, India, Hong Kong, Ukraine, Russia, Thailand, New Zealand, Taiwan, Pakistan, Philippines, Turkey, Israel, Colombia, Peru, Chile, Brazil, Mexico, Germany, France, Denmark, Czech Republic, Bulgaria, Belgium, Canada, Romania, Poland, the Netherlands, Italy, Hungary, South Africa, Sweden, Spain, Slovakia, Australia, Estonia, Greece, United Kingdom, China, Argentina and USA (PO)